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Introduction
In  previous  trials,  functional  imaging  using  mainly 
positron  emission  tomography  (PET)  has  provided 
objective  in  vivo  evidence  that  human  dopamine  (DA) 
-rich fetal ventral mesencephalic (VM) tissue implanted 
in the striatum of Parkinson’s disease (PD) patients can 
survive, grow, release DA, normalize brain metabolism 
and  restore  striatal-cortical  connections,  clinically 
corresponding to significant symptomatic relief in some 
cases [1-3].
PET with 18F-DOPA (see Table 1 for explanation of PET 
ligands) has been consistently used since the early open-
label  [4-8]  up  to  the  more  recent  double-blind  sham-
surgery  controlled  [9,  10]  clinical  trials  to  objectively 
monitor survival and growth of human fetal DA neurons 
grafted in the striatum of PD patients. PET imaging using 
11C-raclopride  after  placebo  or  methamphetamine 
adminis  tration  has  shown  that  graft-derived  DA  cells 
were able to restore the release of endogenous DA in the 
striatum  of  PD  patients  to  almost  normal  levels  [11]. 
Longitudinal  assessments  with  H2
15O  PET  following 
transplantation  have  shown  a  gradual  restoration  of 
movement-related  activation  in  motor  cortical  areas 
indicating that grafted cells can form connections and are 
able to restore striato–cortical networks in the host brain 
[12].
Advances  in  imaging  techniques  including  both  PET 
and  magnetic  resonance  imaging  (MRI)  could  further 
assist  in  the  development  and  monitoring  of  new 
clinically competitive trials.
Discussion
Despite the lack of new clinical trials since the beginning of 
the previous decade, retrospective analysis of data, studies 
in  animal  models  and  long-term  clinical  and  imaging 
observations in the earlier transplanted PD patients have 
allowed us to understand a number of ways that functional 
imaging  could  help  in  understanding  and  monitoring 
outcomes of fetal cell transplantation trials in PD.
There are now up to 16 years of post-transplantation 
18F-DOPA PET follow-up data showing graft viability and 
continuous  clinical  benefit  in  several  transplanted  PD 
patients with fetal VM tissue [11, 13-15]. As the degree of 
motor  impairment  has  been  shown  to  correlate  with 
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the hypothesis that the grafted tissue will survive and 
grow, restore striatal dopaminergic neurotransmission, 
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and cortex and, thereby, produce long-lasting clinical 
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clinical  outcomes  following  fetal  cell  transplantation 
could be associated with the number of viable DA cells 
innervating the striatum as assessed by  18F-DOPA PET. 
This notion could explain the differences in the outcomes 
between open-label trials reporting an average of 50 to 
85% increase in  18F-DOPA uptake associated with good 
clinical  improvement  of  PD  motor  symptoms  and 
reductions in medication requirements [4-8], and the two 
double-blind  sham-surgery  controlled  clinical  trials 
reporting an average of 20 to 40% increases in 18F-DOPA 
uptake associated with poor clinical outcomes during the 
first periods post-transplantation [9, 10].
18F-DOPA PET can also help facilitate patient selection 
and screening as patients with baseline reductions in 18F-
DOPA  uptake  extending  to  the  ventral  part  of  the 
striatum  and  patients  with  reductions  in  18F-DOPA 
uptake  consistent  with  atypical  or  secondary 
Parkinsonism  should  be  excluded  from  these  trials 
[13,  17].  This  knowledge,  which  derived  from  post-hoc 
analysis,  raises  the  possibility  of  a  time  window  for 
optimal  transplantation  outcomes  as  preoperative 
preservation of DA innervation in ventral striatal areas 
seems to be predictive of a better outcome.
During past years, a small number of studies have been 
undertaken  in  order  to  demonstrate  imaging  of  DA 
transporters (DAT) in the grafted striatum. Imaging of 
DAT  with  PET  or  single  photon  emission  computed 
tomography  (SPECT)  could  be  used  as  an  alternative 
technique to  18F-DOPA PET. However, in line with the 
inconsistent  results  observed  in  post-mortem  studies 
with regard to DAT expression in the grafted neurons 
[18,  19],  76Br-FE-CBT  PET  failed  to  visualize  DAT  in 
grafted  striata  enhancing  18F-DOPA  [20],  whereas 
123I-IPT [21] and 123I-FP-CIT [15] SPECT showed robust 
DAT availability and compatible uptake to 18F-DOPA.
Up  to  10  years  post-transplantation  follow-up  data 
using 11C-raclopride PET have shown several cases where 
graft-derived DA cells were able to restore the release of 
endogenous DA in the striatum of PD patients [11, 14, 
17]. The results of these studies suggested that it is very 
likely that the efficient restoration of DA release in large 
parts of the grafted striatum underlies patients’ clinical 
improvement of motor symptoms. Moreover, from PET 
studies  using  H2
15O  we  learned  that  despite  an  early 
stabilization of DA reinnervation in the striatum, graft 
function and integration continue and symptomatic relief 
may also require the functional reafferentation of striato-
thalamo-cortical circuitries in the host brain [12].
Immunosuppression could be another factor related to 
the  outcomes  of  clinical  trials,  although  the  role  of 
neuroinflammation  in  influencing  the  outcome  of 
transplantation procedures in PD is not known. There is 
evidence showing that long-term immunosuppresion can 
be withdrawn without interfering with graft survival or 
the  motor  recovery  induced  by  transplantation  [17]. 
Additional  evidence  indicated  that  the  occurrence  of 
graft-induced  dyskinesias  (GIDs),  one  of  the  most 
disabling  side  effects  of  cell  therapy  in  PD,  could  be 
induced by inflammatory and immune responses around 
the  graft.  In  one  study  GIDs  developed  after 
discontinuation  of  immunosuppressive  therapy,  with 
signs of an inflammatory reaction around the grafts in 
autopsied  cases  [10].  Although  imaging  studies  have 
never  been  employed,  PET  imaging  can  be  used  to 
explore the possible role of host inflammatory reaction in 
relation to fetal cell transplantation outcomes in PD using 
markers  of  microglial  activation  such  as  11C-PK11195 
PET or any of the other recently developed translocator 
protein (TSPO) PET ligands.
GIDs are a severe adverse effect of fetal cell transplanta-
tion  in  PD  hindering  the  further  development  of  cell 
Table	1.	Positron	emission	tomography	techniques
Technique	 Target	 Use
18F-DOPA PET   Aromatic amino acid decarboxylase (AADC)     Provides measures of AADC activity and allows an indirect measure 
of DA storage within the DA terminals.
11C-raclopride PET  Post-synaptic DA D2 receptors     Is a subject to competitive displacement by endogenous DA. 
Acute administration of substances such as amphetamine, 
methylphenidate, or L-DOPA, which are known to increase the levels 
of extracellular DA result in a reduction of 11C-raclopride binding.
H2
15O PET  Regional cerebral blood flow (rCBF)   Brain activation and regional cerebral metabolism.
76Br-FE-CBT PET  Dopamine transporter (DAT)  Marker of presynaptic DA terminals integrity and DAT availability
123I-IPT SPECT  DAT  Marker of presynaptic DA terminals integrity and DAT availability
123I-FP-CIT SPECT  DAT  Marker of presynaptic DA terminals integrity and DAT availability
11C-PK11195 PET  Translocator protein (TSPO)    Is an 18 kDa protein of the outer mitochondrial membrane that is 
upregulated with activation of microglia
11C-DASB PET  5-HT transporter (SERT)  Marker of presynaptic 5-HT terminals integrity and SERT availability
11C-dihydrotetrabenazine (DTBZ) PET  Vesicular monoamine transporter (VMAT2)   Marker of presynaptic monoaminergic terminals integrity
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ing the several theories proposed [25], recent data imply 
that  the  development  of  GIDs  could  be  related  to  the 
composition  of  grafted  tissue  [14],  as  human  fetal  VM 
tissue  contains  a  varied  proportion  of  non-DA  neurons 
[26], including serotonin (5-HT) neurons. 11C-DASB PET 
and a clinical trial with an agent dampening transmitter 
release  from  5-HT  neurons  was  used  to  show  a  causal 
relationship between mishandling of DA release from the 
graft-derived 5-HT hyperinnervation in the striatum of PD 
patients and the occurrence of GIDs [14, 15]. Furthermore, 
it was suggested that the high ratios between 5-HT and 
DA neurons and between 5-HT transporters (SERT) and 
DAT could be the driving factor for the development of 
GIDs  [14,  15,  25].  Therefore,  these  results  suggest  that 
achieving normal striatal 5-HT/DA and SERT/DAT ratios 
following  transplantation  of  fetal  tissue  or  stem  cells 
should be necessary to avoid the development of GIDs.
Recent advances in MRI techniques allow us to examine 
the brain in a way that was not previously possible. The 
examination  of  functional  connectivity  between  brain 
regions is now possible using resting-state functional MRI 
(fMRI). These resting state networks (RSNs) are believed 
to  reflect  functional  communication  between  brain 
regions and could be very informative in providing insights 
of large-scale neuronal communication during restorative 
therapies such as fetal cell transplantation in PD [27-29]. 
FMRI  paradigms  with  motor  execution  (ME)  tasks  are 
now widely employed to understand brain activation in the 
corresponding  regions.  Diffusion  Tensor  Imaging  (DTI) 
offers a method to assess white matter (WM) structural 
connectivity  and  thereby,  alterations  underlying 
neurodegenerative diseases such as PD and the potential 
effects of restorative therapies [28, 30].
Conclusions
A  new  European  Commission-funded  multicenter  trial 
under  the  name  Transeuro  was  recently  launched  for 
a  new  round  of  fetal  cell  transplantation  trials   
(www.transeuro.org.uk).  Functional  imaging  protocols 
for this or any other future trials employing fetal or stem 
cells will undoubtedly benefit from the lessons learned 
from over two decades of research.
An  optimized  functional  imaging  protocol  (Table  2) 
using PET should search for a ligand tagging a specific to 
DA presynaptic terminal location in order to assess the 
DA-rich graft survival and growth. A good candidate is 
DAT; however, post-mortem and in vivo imaging results 
with  PET  and  SPECT  have  been  inconsistent.  11C-
dihydrotetrabenazine (DTBZ) PET measuring the density 
of the vesicular monoamine transporter (VMAT2) could 
serve as an alternative, but to date there are no 11C-DTBZ 
PET data on the expression and survival of VMAT2 in 
VM  tissue  grafts  and  VMAT2  is  also  present  in  other 
monoaminergic  systems.  Therefore,  18F-DOPA  PET 
remains today the standard for monitoring survival and 
growth of grafted DA cells. According to data from open-
label and double blind trials it appears that a short-term 
increase  in  18F-DOPA  uptake  of  more  than  50%  from 
baseline  is  necessary  to  achieve  clinically  valuable 
antiparkinsonian effects. Measures of  18F-DOPA uptake 
at baseline can also provide valuable information to assist 
in  the  selection  of  patients  for  trials  of  cell-based  DA 
therapies  in  PD  by  excluding  those  showing  reduced 
uptake  in  the  ventral  striatum.  11C-raclopride  PET 
together with a competitive displacement challenge (for 
example,  amphetamine,  methylphenidate,  or  L-DOPA) 
could be used to visualize a graft’s ability to release DA. 
11C-DASB PET together with 18F-DOPA PET and markers 
of DAT availability can be used to calculate binding ratios 
reflecting proportions of 5-HT to DA neurons and SERT 
to  DAT  binding  sites  and,  therefore,  assist  in  the 
preparation  of  grafts  during  preoperational  screening 
and,  hence,  prevent  and  monitor  the  development  of 
GIDs  postoperational.  Inflammatory  and  immune 
responses around the graft alongside the effect of immuno-
suppressive therapy on transplantation outcomes could be 
assessed with  11C-PK11195 or one of the other recently 
Table	2.	Examples	of	imaging	techniques	used	in	the	past	and	that	can	be	used	in	the	future
Assessments		 Previous	functional	imaging	protocols	 Optimized	functional	imaging	protocols
DA-rich graft survival and growth  18F-DOPA PET   18F-DOPA PET
Patient selection  –  18F-DOPA PET
DA release from the graft  11C-raclopride with challenge  11C-raclopride with challenge
Graft-derived 5-HT innervation and growth  –  11C-DASB
Graft-induced dyskinesias  –  11C-DASB PET/18F-DOPA PET ratio
    11C-DASB PET/123I-FP-CIT SPECT ratio
Inflammatory and immune responses around the graft   –  11C-PK11195
Brain activation during movement  H2
15O PET with motor execution tasks   fMRI with motor execution tasks
Functional connectivity between brain regions   –  Resting-state fMRI
White matter structural connectivity   –  Diffusion Tensor Imaging
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techniques such as RSNs fMRI and DTI could assist in 
the  assessment  of  functional  and  WM  structural 
connectivity between the graft and the host brain while 
ME  tasks  could  be  employed  replacing  previous 
paradigms with H2 15O PET.
Although functional imaging cannot currently be used as 
a primary endpoint in clinical transplantation trials, if used 
appropriately, it can provide researchers with an additional 
valuable  in  vivo  tool  alongside  clinical  observations.  It  is 
worth noting, however, that previous knowledge has shown 
that  in  order  to  efficiently  monitor  cell  replacement 
therapies in PD with functional imaging, long period follow-
up  assessments  are  needed  and  conclusions  cannot  be 
ultimately achieved with short follow-up periods.
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